Taiko Pharmaceutical Co.,Ltd. (TYO:4574)
Japan · Delayed Price · Currency is JPY 277.00
-3.00 (-1.07%)
Jul 16, 2025, 3:30 PM JST
Taiko Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 6,065 | 6,292 | 6,120 | 5,040 | 11,299 | 22,456 | Upgrade | |
Revenue Growth (YoY) | -4.19% | 2.81% | 21.43% | -55.39% | -49.68% | 50.05% | Upgrade |
Cost of Revenue | 2,519 | 2,626 | 3,543 | 3,961 | 8,552 | 6,917 | Upgrade |
Gross Profit | 3,546 | 3,666 | 2,577 | 1,079 | 2,747 | 15,539 | Upgrade |
Selling, General & Admin | 3,086 | 3,036 | 3,583 | 4,157 | 7,694 | 9,294 | Upgrade |
Operating Expenses | 3,086 | 3,036 | 3,583 | 4,157 | 7,694 | 9,267 | Upgrade |
Operating Income | 460 | 630 | -1,006 | -3,078 | -4,947 | 6,272 | Upgrade |
Interest Expense | -7 | -8 | -8 | -10 | -6 | - | Upgrade |
Interest & Investment Income | 26 | 30 | 25 | 5 | 3 | 8 | Upgrade |
Currency Exchange Gain (Loss) | -4 | 39 | 31 | 59 | 50 | -35 | Upgrade |
Other Non Operating Income (Expenses) | -6 | -2 | -291 | -330 | -1,231 | -226 | Upgrade |
EBT Excluding Unusual Items | 469 | 689 | -1,249 | -3,354 | -6,131 | 6,019 | Upgrade |
Gain (Loss) on Sale of Investments | 353 | 6 | 193 | -82 | 60 | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 76 | - | - | - | Upgrade |
Asset Writedown | -240 | -240 | -2,506 | -98 | -2,456 | -106 | Upgrade |
Legal Settlements | - | - | - | -499 | -359 | -62 | Upgrade |
Other Unusual Items | -78 | 111 | -78 | -837 | -2 | -41 | Upgrade |
Pretax Income | 504 | 566 | -3,564 | -4,870 | -8,888 | 5,810 | Upgrade |
Income Tax Expense | -214 | -332 | 47 | 25 | 706 | 1,632 | Upgrade |
Net Income | 718 | 898 | -3,611 | -4,895 | -9,594 | 4,178 | Upgrade |
Net Income to Common | 718 | 898 | -3,611 | -4,895 | -9,594 | 4,178 | Upgrade |
Net Income Growth | - | - | - | - | - | 70.32% | Upgrade |
Shares Outstanding (Basic) | 50 | 50 | 47 | 44 | 44 | 43 | Upgrade |
Shares Outstanding (Diluted) | 50 | 50 | 47 | 44 | 44 | 43 | Upgrade |
Shares Change (YoY) | 2.45% | 5.96% | 8.62% | 0.21% | 0.35% | 1.32% | Upgrade |
EPS (Basic) | 14.30 | 17.89 | -76.25 | -112.27 | -220.51 | 96.96 | Upgrade |
EPS (Diluted) | 14.30 | 17.89 | -76.25 | -112.27 | -220.51 | 96.37 | Upgrade |
EPS Growth | - | - | - | - | - | 68.07% | Upgrade |
Free Cash Flow | - | 205 | -404 | -2,058 | -3,071 | -4,881 | Upgrade |
Free Cash Flow Per Share | - | 4.08 | -8.53 | -47.20 | -70.58 | -112.59 | Upgrade |
Dividend Per Share | - | - | - | - | - | 23.667 | Upgrade |
Dividend Growth | - | - | - | - | - | 136.67% | Upgrade |
Gross Margin | 58.47% | 58.26% | 42.11% | 21.41% | 24.31% | 69.20% | Upgrade |
Operating Margin | 7.58% | 10.01% | -16.44% | -61.07% | -43.78% | 27.93% | Upgrade |
Profit Margin | 11.84% | 14.27% | -59.00% | -97.12% | -84.91% | 18.61% | Upgrade |
Free Cash Flow Margin | - | 3.26% | -6.60% | -40.83% | -27.18% | -21.74% | Upgrade |
EBITDA | 717 | 886 | -302 | -2,341 | -4,006 | 6,901 | Upgrade |
EBITDA Margin | 11.82% | 14.08% | -4.93% | -46.45% | -35.45% | 30.73% | Upgrade |
D&A For EBITDA | 257 | 256 | 704 | 737 | 941 | 629.33 | Upgrade |
EBIT | 460 | 630 | -1,006 | -3,078 | -4,947 | 6,272 | Upgrade |
EBIT Margin | 7.58% | 10.01% | -16.44% | -61.07% | -43.78% | 27.93% | Upgrade |
Effective Tax Rate | - | - | - | - | - | 28.09% | Upgrade |
Advertising Expenses | - | 767 | 979 | 806 | 3,005 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.